Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
2016-004356-30Phase 4Unknown
- Sponsor
- AbbVie Inc.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ibrutinib in throat cancer (2 arms), sponsored by AbbVie Inc. Primary endpoint: Long-term safety. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
throat cancer
Beyond the preview
Go deeper on 2016-004356-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004356-30.